In conclusion, our study reports a therapeutic effect of pharmacological targeting of SHP2 on renal injury in an animal DN model, and also highlights a critical role of SHP2/ERK/NF-κB pathway-induced production of proinflammatory cytokines and -elicited inflammation in promoting renal injury in DN pathology (Fig. 9). Here, NFKB1 is linked to liver dysplastic nodule.